GSDME and lung carcinoma: Additionally, dasatinib, a multi-kinase inhibitor, can induce pyroptosis in GSDME‐expressing lung cancer and neuroblastoma, and increase the expression of GSDMD and GSDME in a p53‐independent manner [38].